Comparison · NCT03852628-7008cbab
2mg Buprenex and 380mg Vivitrol vs Placebo: Number of Participants With a Reduction in CAPS-5 Total Symptom Severity Score (TSSS) of 10 or More Points
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 2mg Buprenex and 380mg Vivitrol vs Placebo: Number of Participants With a Reduction in CAPS-5 Total Symptom Severity Score (TSSS) of 10 or More Points. Trial comparisons, record NCT03852628-7008cbab. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03852628-7008cbab
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.5 | 0.326 | 0.674 | wilson | |
| Risk in group 2 | 0.556 | 0.373 | 0.724 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0556 | -0.298 | 0.196 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.9 | 0.545 | 1.49 | log | |
| Odds ratio, group 1 over group 2 | 0.8 | 0.277 | 2.31 | log | |
| Number needed to treat, for one fewer participant with the outcome on 2mg Buprenex and 380mg Vivitrol than on Placebo | 18 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 2mg Buprenex and 380mg Vivitrol | 2mg Buprenex and 380mg Vivitrol~Buprenex (buprenorphine) 2mg sublingual (SL) (taken every day for 12 weeks) , with Vivitrol (naltrexone) 380mg intramuscular injection (IM) (given every 4 weeks)~2mg Buprenex and 380mg Vivitrol: Daily 2mg SL BUP (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8 ) IM NLTRX | 14 | 28 | OG000 |
| Group 2 | Placebo | Placebo (SL pill qd, IM injection q4weeks)~Placebo pill (taken sublingual every day for 12 weeks) and IM placebo (given intramuscular injection, every 4 weeks at baseline, week4 and week8)~Placebo (SL pill qd, IM injection q4weeks): Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo | 15 | 27 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With a Reduction in CAPS-5 Total Symptom Severity Score (TSSS) of 10 or More Points
- Description
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a 30-item structured interview to assess PTSD diagnosis and symptom severity. The CAPS-5 produces a PTSD Total Symptom Severity Score (TSSS) that ranges from 0 to 80, with a higher score indication worse PTSD symptoms. For this study, a reduction in PTSD symptoms is defined as a 10 or more point decrease in the CAPS-5 Total Symptom Severity Score (TSSS) from baseline to week 8.
- Time frame
- Baseline and 8 weeks
- Population
- All randomized participants that completed the baseline and week 8 visit.
Source ClinicalTrials.gov
Trial
- Title
- Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD
- NCT number
- NCT03852628
- Phases
- PHASE2
- Conditions
- Post Traumatic Stress Disorder, Alcohol Abuse
- Interventions
- 2mg Buprenex and 380mg Vivitrol, Placebo (SL pill qd, IM injection q4weeks)
- Lead sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- Results first posted
- 2023-06-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03852628?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03852628-7008cbab